• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Genfit S.A. ADR (NQ: GNFT )

    4.440 +0.040 (+0.91%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 681
    Open 4.310
    Bid (Size) 3.000 (4)
    Ask (Size) 4.850 (3)
    Prev. Close 4.400
    Today's Range 4.310 - 4.440
    52wk Range 2.893 - 6.050
    Shares Outstanding 38,888,379
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
    The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
    Via Benzinga
    Exposures Product Safety
    Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    +10.17%
    +10.17%
    1 Month
    +5.59%
    +5.59%
    3 Month
    -2.84%
    -2.84%
    6 Month
    +18.72%
    +18.72%
    1 Year
    +27.59%
    +27.59%

    More News

    Read More
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Analyst Expectations for Genfit's Future
    Via Benzinga
    Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
    Via Benzinga
    Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Earnings Scheduled For April 4, 2024
    Via Benzinga
    Why CymaBay Morphed From Dollar Stock To Biotech Rocket
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
    Via Investor's Business Daily
    Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
    Via Benzinga
    Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
    Via Benzinga
    Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
    Via Benzinga
    Earnings Scheduled For April 13, 2023
    Via Benzinga
    The 7 Best Biotech Stocks to Buy for February 2023
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Earnings Scheduled For September 28, 2022
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.